AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris, December 18, 2025, 7.15pm CET AB Science SA (Euronext - FR0010557264 - AB) ...
AB Science SA (Euronext - FR0010557264 - AB) announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast ...
The average one-year price target for AB Science (ENXTPA:AB) has been revised to €4.31 / share. This is an increase of 22.25% from the prior estimate of €3.53 dated September 27, 2025. The price ...
Operating income as of June 30, 2025, corresponds to a loss of €2,728,000, compared to a loss of €3,582,000 as of June 30, 2024, representing a decrease in the operating deficit of €854,000 (23.8%).
AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA Paris, 07 ...
AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of a new article on the preprint platform MedRxiv, presenting a post-hoc subgroup analysis of the phase 2b/3 AB10015 study ...
Ab Science ( (ABSCF)) has released its Q2 earnings. Here is a breakdown of the information Ab Science presented to its investors. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results